Literature DB >> 35241835

The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.

Merav Cohen1,2,3,4, Amir Giladi5,6, Oren Barboy5, Amos Tanay7, Miriam Merad8,9,10, Ido Amit11, Pauline Hamon12,13, Baoguo Li5, Mor Zada5,14, Anna Gurevich-Shapiro5,14,15, Cristian Gabriel Beccaria16, Eyal David5, Barbara B Maier12,13, Mark Buckup12,13, Iris Kamer17, Aleksandra Deczkowska5,18, Jessica Le Berichel12,13, Jair Bar14,17, Matteo Iannacone16.   

Abstract

Despite their key regulatory role and therapeutic potency, the molecular signatures of interactions between T cells and antigen-presenting myeloid cells within the tumor microenvironment remain poorly characterized. Here, we systematically characterize these interactions using RNA sequencing of physically interacting cells (PIC-seq) and find that CD4+PD-1+CXCL13+ T cells are a major interacting hub with antigen-presenting cells in the tumor microenvironment of human non-small cell lung carcinoma. We define this clonally expanded, tumor-specific and conserved T-cell subset as T-helper tumor (Tht) cells. Reconstitution of Tht cells in vitro and in an ovalbumin-specific αβ TCR CD4+ T-cell mouse model, shows that the Tht program is primed in tumor-draining lymph nodes by dendritic cells presenting tumor antigens, and that their function is important for harnessing the antitumor response of anti-PD-1 treatment. Our molecular and functional findings support the modulation of Tht-dendritic cell interaction checkpoints as a major interventional strategy in immunotherapy.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35241835     DOI: 10.1038/s43018-022-00338-5

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  49 in total

Review 1.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

2.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.

Authors:  Miranda L Broz; Mikhail Binnewies; Bijan Boldajipour; Amanda E Nelson; Joshua L Pollack; David J Erle; Andrea Barczak; Michael D Rosenblum; Adil Daud; Diane L Barber; Sebastian Amigorena; Laura J Van't Veer; Anne I Sperling; Denise M Wolf; Matthew F Krummel
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

Review 3.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

4.  PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.

Authors:  Soyoung A Oh; Dai-Chen Wu; Jeanne Cheung; Armando Navarro; Huizhong Xiong; Rafael Cubas; Klara Totpal; Henry Chiu; Yan Wu; Laetitia Comps-Agrar; Andrew M Leader; Miriam Merad; Merone Roose-Germa; Soren Warming; Minhong Yan; Jeong M Kim; Sascha Rutz; Ira Mellman
Journal:  Nat Cancer       Date:  2020-06-22

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 6.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 7.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

8.  Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Authors:  Christopher S Garris; Sean P Arlauckas; Rainer H Kohler; Marcel P Trefny; Seth Garren; Cécile Piot; Camilla Engblom; Christina Pfirschke; Marie Siwicki; Jeremy Gungabeesoon; Gordon J Freeman; Sarah E Warren; SuFey Ong; Erica Browning; Christopher G Twitty; Robert H Pierce; Mai H Le; Alain P Algazi; Adil I Daud; Sara I Pai; Alfred Zippelius; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2018-12-11       Impact factor: 43.474

9.  A conserved dendritic-cell regulatory program limits antitumour immunity.

Authors:  Barbara Maier; Andrew M Leader; Steven T Chen; Navpreet Tung; Christie Chang; Jessica LeBerichel; Aleksey Chudnovskiy; Shrisha Maskey; Laura Walker; John P Finnigan; Margaret E Kirkling; Boris Reizis; Sourav Ghosh; Natalie Roy D'Amore; Nina Bhardwaj; Carla V Rothlin; Andrea Wolf; Raja Flores; Thomas Marron; Adeeb H Rahman; Ephraim Kenigsberg; Brian D Brown; Miriam Merad
Journal:  Nature       Date:  2020-03-25       Impact factor: 49.962

10.  cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity.

Authors:  Stephen T Ferris; Vivek Durai; Renee Wu; Derek J Theisen; Jeffrey P Ward; Michael D Bern; Jesse T Davidson; Prachi Bagadia; Tiantian Liu; Carlos G Briseño; Lijin Li; William E Gillanders; Gregory F Wu; Wayne M Yokoyama; Theresa L Murphy; Robert D Schreiber; Kenneth M Murphy
Journal:  Nature       Date:  2020-08-12       Impact factor: 49.962

View more
  7 in total

1.  Untangling the threads of immunotherapy research.

Authors: 
Journal:  Nat Cancer       Date:  2022-03

2.  DePICting T cell-APC crosstalk in cancer.

Authors:  Ting Zhang; Chen Dong
Journal:  Nat Cancer       Date:  2022-03

3.  Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade.

Authors:  Baolin Liu; Yuanyuan Zhang; Dongfang Wang; Xueda Hu; Zemin Zhang
Journal:  Nat Cancer       Date:  2022-09-22

4.  Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.

Authors:  Denise Lau; Sonal Khare; Michelle M Stein; Prerna Jain; Yinjie Gao; Aicha BenTaieb; Tim A Rand; Ameen A Salahudeen; Aly A Khan
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

Review 5.  Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era.

Authors:  Collin J Larkin; Víctor A Arrieta; Hinda Najem; Gongbo Li; Peng Zhang; Jason Miska; Peiwen Chen; Charles David James; Adam M Sonabend; Amy B Heimberger
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

6.  Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.

Authors:  Carlos Martinez-Gomez; Marie Michelas; Clara-Maria Scarlata; Anna Salvioni; Carlos Gomez-Roca; Victor Sarradin; Françoise Lauzéral-Vizcaino; Virginie Féliu; Agnès Dupret-Bories; Gwénaël Ferron; Jérôme Sarini; Christel Devaud; Jean-Pierre Delord; Camille-Charlotte Balança; Alejandra Martinez; Maha Ayyoub
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

7.  Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Authors:  Espen Basmo Ellingsen; Gergana Bounova; Iliana Kerzeli; Irantzu Anzar; Donjete Simnica; Elin Aamdal; Tormod Guren; Trevor Clancy; Artur Mezheyeuski; Else Marit Inderberg; Sara M Mangsbo; Mascha Binder; Eivind Hovig; Gustav Gaudernack
Journal:  J Transl Med       Date:  2022-09-11       Impact factor: 8.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.